Concurrent infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients positive for human
immunodeficiency virus (HIV) is relatively common. The treatment of co-infected individuals is rather complex because
the anti-viral therapy may be associated with drug-resistance, hepatotoxicity and lack of response. Herein, we present a
summary of the available compounds and the recent recommendations concerning the therapeutic management of
HIV/HBV and HIV/HCV co-infections.
Keywords: HIV, HBV, HCV, co-infection, treatment, drugs, hepatitis B, hepatocellular carcinoma, adefovir, lamivudine, entecavir
Rights & PermissionsPrintExport